Concepedia

Author

Lorenzo Antonuzzo

Azienda Ospedaliero-Universitaria CareggiORCID

Also Known As

Amelia Altavilla, Antonuzzo Lorenzo, Antonuzzo, L., Antonuzzo, Lorenzo, Armin Gerger, Bruno Daniele, Egbert Smit, Federica Di Costanzo, L Antonuzzo, L. ANTONUZZO

412

Publications

7.3K

Citations

43

H-Index

74

Concepts

All Affiliations

Azienda Ospedaliero-Universitaria CareggiIstituti di Ricovero e Cura a Carattere ScientificoUniversity of FlorenceFondazione IRCCS Istituto Nazionale dei TumoriIstituto Oncologico Veneto
LA

About

Lorenzo Antonuzzo is an author at Azienda Ospedaliero-Universitaria Careggi specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

42

2.2K

2

Health Sciences

9

9

466

3

Biostatistics

2

2

118

4

Public Health

1

1

73

5

Diabetes

1

1

87

Lorenzo Antonuzzo

×

108

Publications

5.3K

Citations

37

H-Index

YearCitations

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi,

New England Journal of Medicine

2023

574

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini,

The Lancet Oncology

2020

309

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio,

The Lancet Oncology

2022

246

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Thomas Powles, James W.F. Catto, Matthew D. Galsky,

New England Journal of Medicine

2024

245

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

Gianluca Masi, Lisa Salvatore, Luca Boni,

Annals of Oncology

2015

164

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

Filippo Pietrantonio, M. Caporale, Federica Morano,

International Journal of Cancer

2016

142

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial

Federica Morano, Alessandra Raimondi, Filippo Pagani,

Journal of Clinical Oncology

2022

120

Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data

Margherita Rimini, Lorenzo Fornaro, Sara Lonardi,

Liver International

2023

110

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, Nicola Fazio, Carlos López,

Journal of Clinical Oncology

2021

103

Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors

Francesco Panzuto, Maria Rinzivillo, Nicola Fazio,

The Oncologist

2014

102

Page 1